Certara (CERT)
Supports drug-development decisions with biosimulation software, scientific technology, and services.
Something off on this page? Send us feedback.
Provides biosimulation software, scientific technology, and services for drug developers from discovery through market access. Its platform combines modeling, clinical-data readiness, and cheminformatics capabilities assembled through acquisitions.
Provides biosimulation software, scientific technology, and services used in drug discovery, preclinical and clinical research, regulatory submissions, and market access. The platform grew from the combination of Tripos International and Pharsight and later added Simcyp, Pinnacle 21, and Chemaxon capabilities. Its worldwide workforce spans dozens of countries.
Modeling and simulation underpin the drug-development workflows it supports, while Pinnacle 21 addresses clinical-data fitness and submission readiness and Chemaxon serves in-silico research. The company completed the sale of its global medical-writing and related regulatory-services business in 2026, defining the current portfolio boundary.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | Barclays | Reiterate | Rating: —Target: $16 | Target: $7.50 |
| May 12, 2026 | Craig-Hallum | Reiterate | Rating: —Target: $16 | Target: $8 |
| Mar 6, 2026 | Barclays | Downgrade | ||
| Feb 26, 2026 | Leerink Partners | Target | Target: $13 | Target: $10 |
| Jan 6, 2026 | Leerink Partners | Upgrade | Target: — | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $184.1M · Total debt $291.8M · Total assets $1.40B · Shareholders' equity $966.5M
- Revenue
- $93.3M
- Operating income
- −$196.0K
- Net income
- −$55.3M
No dividends on record.
| Institutions | 88.81% | 135.47M shares | |
|---|---|---|---|
| 245 holders · as of Jun 30, 2026 | |||
| Insiders | 2.71% | 4.13M shares | |
| 18 holders · as of Jul 17, 2026 | |||
| Strategic holders | 9.15% | 13.96M shares | |
| 1 holder · as of Jan 25, 2024 | |||
| Adds to | 100.67% | ||
152.54M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 100.67%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 12.34% | 18.82M | as of Jun 30, 2026 |
BlackRock, Inc.Strategic | 9.15% | 13.96M | filed Jan 25, 2024 |
Deerfield Management Company, L.P. (Series C)Institution | 4.93% | 7.51M | as of Jun 30, 2026 |
Haveli Investment Management LLCInstitution | 4.85% | 7.40M | as of Jun 30, 2026 |
Jefferies Financial Group Inc.Institution | 4.65% | 7.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 11, 2025 | William F. Feehery | director, officer: CHIEF EXECUTIVE OFFICER | +24,096 | $8.30 |
- Simulations Plus
Biosimulation software and consulting across drug development
- ICON
Clinical research services with industry-standard pharmacometrics software
- Schrödinger
Physics-based computational platform for molecular drug discovery
- IQVIA
Technology-enabled clinical research and healthcare analytics services
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Certara | $8.77 | −0.79% | $1.33B | — | 22.8 | 3.2 | −10.8% |
| Simulations Plus | $18.41 | 0.00% | $372.7M | 46.1 | 21.7 | 4.5 | +7.5% |
| ICON | $98.33 | −41.20% | $12.98B | 39.8 | 15.0 | 1.6 | +2.3% |
| Schrödinger | $30.73 | +0.10% | $2.26B | — | — | 8.7 | +7.5% |
| IQVIA | $270.09 | +0.01% | $44.42B | 33.5 | 19.9 | 2.6 | +8.7% |
| Median | 39.8 | 19.9 | 3.6 | +7.5% |